Sofia S. Pereira

Prof. Sofia S. Pereira

University of Porto, Porto, Portugal
orcid

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 June 2017 in Journal of Endocrinological Investigation
Verified
Journal Article
Closed access
PDF file
JCJ. Crespigio
J. Crespigio
LBL. C. L. Berbel
L. C. L. Berbel
MDM. A. Dias
M. A. Dias
RBR. F. Berbel
R. F. Berbel
SPSofia S. Pereira
Sofia S. Pereira
TMT. L. Mazzuco
T. L. Mazzuco

2 December 2021 in Reviews in Endocrine and Metabolic Disorders
Verified
Journal Article
Open access
PDF file
MVMatilde Vaz
Matilde Vaz
SPSofia S. Pereira
Sofia S. Pereira
MMMariana Monteiro
Mariana Monteiro
Metabolomics emerged as an important tool to gain insights on how the body responds to therapeutic interventions. Bariatric surgery is the most effective treatment for severe obesity and obesity-related co-morbidities. Our aim was to conduct a systematic review of the available data on metabolomics profiles that characterize patients submitted to different bariatric surgery procedures, which could be useful to predict clinical outcomes including weight loss and type 2 diabetes remission. For that, the Preferred Reporting Items for Systematic Reviews and Meta-Analyses - PRISMA guidelines were followed. Data from forty-seven original study reports addressing metabolomics profiles induced by bariatric surgery that met eligibility criteria were compiled and summarized. Amino acids, lipids, energy-related and gut microbiota-related were the metabolite classes most influenced by bariatric surgery. Among these, higher pre-operative levels of specific lipids including phospholipids, long-chain fatty acids and bile acids were associated with post-operative T2D remission. As conclusion, metabolite profiling could become a useful tool to predict long term response to different bariatric surgery procedures, allowing more personalized interventions and improved healthcare resources allocation.

27 August 2018 in Cancers
Verified
Journal Article
Open access
PDF file
ASAna P. Santos
Ana P. Santos
Ana SantosAna Santos
Ana Santos
CCClara Castro
Clara Castro
LRLuís Raposo
Luís Raposo
SPSofia S. Pereira
Sofia S. Pereira
DPDuarte Pignatelli
Duarte Pignatelli
The determinants for gastroenteropancreatic neuroendocrine tumors (GEP-NET) recent burden are matters of debate. Obesity and metabolic syndrome (MetS) are well established risks for several cancers even though no link with GEP-NETs was yet established. Our aim in this study was to investigate whether well-differentiated GEP-NETs were associated with obesity and MetS. Patients with well-differentiated GEP-NETs (n = 96) were cross-matched for age, gender, and district of residence with a control group (n = 96) derived from the general population in a case-control study. Patients presented gastro-intestinal (75.0%) or pancreatic (22.9%) tumors, grade G1 (66.7%) or G2 (27.1%) with localized disease (31.3%), regional metastasis (16.7%) or distant metastasis (43.8%) at diagnosis, and 45.8% had clinical hormonal syndromes. MetS was defined according to Joint Interim Statement (JIS) criteria. Well-differentiated GEP-NETs were associated with MetS criteria as well as the individual components’ waist circumference, fasting triglycerides, and fasting plasma glucose (p = 0.003, p = 0.002, p = 0.011 and p < 0.001, respectively). The likelihood of the association was higher when the number of individual MetS components was greater than four. MetS and some individual MetS components including visceral obesity, dyslipidemia, and increased fasting glucose are associated with well-differentiated GEP-NET. This data provides a novel insight in unraveling the mechanisms leading to GEP-NET disease.

11 December 2018 in International Journal of Obesity
Verified
Journal Article
Closed access
PDF file
SPSofia S. Pereira
Sofia S. Pereira
MGMarta Guimarães
Marta Guimarães
RARui Almeida
Rui Almeida
APAna M. Pereira
Ana M. Pereira
CLCarolina Brito Lobato
Carolina Brito Lobato
MMMariana Monteiro
Mariana Monteiro

4 August 2019 in Endocrine
Verified
Journal Article
Open access
PDF file
SPSofia S. Pereira
Sofia S. Pereira
MMMariana Monteiro
Mariana Monteiro
MCMadalena M. Costa
Madalena M. Costa
ÂMÂngela Moreira
Ângela Moreira
Marco AlvesMarco Alves
Marco Alves
DPDuarte Pignatelli
Duarte Pignatelli
Purpose Clinical outcomes of adrenocortical carcinomas (ACC) could be improved by using novel treatment targets based on the recent advances of tumor biology knowledge. Insulin-like growth factor 2 (IGF2) protein expression is usually 8–80 fold higher in ACC when compared to normal adrenal glands (N-AG) or adrenocortical adenomas (ACA), despite the fact that the biological features of high vs. low IGF2 expressing ACC have not yet been well characterized. Our goal was to understand the IGF2 role in ACC biology by focusing in several cancer hallmarks, including cell proliferation, viability, invasion, and metabolism. Methods IGF2 immunohistochemistry expression was evaluated in ACC (n = 13), non-functioning adrenocortical adenoma (ACAn) (n = 14), and N-AG (n = 9). The effects of IGF2 (50, 100 ng/mL) in cell proliferation, viability, invasion, and metabolism, as well as in MAPK/ERK and mTOR pathways activation and N-cadherin expression, were evaluated in the ACC human cell line H295R. Results IGF2 expression was increased in ACC compared to ACAn and N-AG. Exposure to 100 ng/mL of IGF2 increased H295R cell proliferation and viability. mTOR inhibition reverted IGF2 triggered cell proliferation and viability while MEK/MAPK/ERK inhibition only reverted IGF2 effects on cell proliferation. IGF2 at a 50 ng/mL concentration increased the glycolytic flux and decreased glutamine consumption. Conclusions IGF2 is an excellent marker to differentiate ACC from ACAn. In addition, IGF2 was demonstrated to influence adrenocortical cancer cell proliferation, metabolism, and viability, but not the cell invasion. These data support that different IGF2 concentrations in ACC can be responsible for different biological behaviors of ACC.

1 November 2015 in Surgery for Obesity and Related Diseases
Verified
Journal Article
Closed access
TGTiago P. Guedes
Tiago P. Guedes
SMSofia Martins
Sofia Martins
MCMadalena Costa
Madalena Costa
SPSofia S. Pereira
Sofia S. Pereira
TMTiago Morais
Tiago Morais
MMMariana Monteiro
Mariana Monteiro